Immune thrombocytopenic purpura (ITP) refers to a rare autoimmune disorder in which the body's immune system destroys the blood cells that help in blood clotting (platelets). In the United States, the incidence of this disease is around 66 cases per 1,000,000 every year in adults. Treatments such as corticosteroids, immunoglobulins, and thrombopoietin receptor agonists (TPO-RAs) are available in the market. However, a substantial portion of the patient population fails to achieve sustained remission. Recent advancements in the treatment landscape are likely to introduce several promising immune thrombocytopenic purpura drugs in the coming years.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing immune thrombocytopenic purpura pipeline development activities.
Common immune thrombocytopenic purpura therapeutics include corticosteroids such as prednisone and dexamethasone that work by suppressing immune activity and increasing platelet counts. Intravenous immunoglobulin (IVIg) is another first-line treatment that temporarily increases platelet counts by modulating the immune response. Advancements in ITP therapeutics, coupled with evidence-based immune thrombocytopenic purpura treatment guidelines, are anticipated to improve patient outcomes and support pipeline expansion.
As per the studies conducted in England and Denmark, childhood immune thrombocytopenic purpura occurs in about 10 to 40 cases per 1,000,000 each year.
This product will be delivered within 3-5 business days.
Report Coverage
The Immune Thrombocytopenic Purpura Drug Pipeline Insight Report by the publisher gives comprehensive insights into immune thrombocytopenic purpura therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for immune thrombocytopenic purpura. The immune thrombocytopenic purpura report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The immune thrombocytopenic purpura pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with immune thrombocytopenic purpura treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing immune thrombocytopenic purpura pipeline development activities.
Immune Thrombocytopenic Purpura Drug Pipeline Outlook
Immune thrombocytopenic purpura is an autoimmune disorder characterized by low platelet counts, leading to an increased risk of bleeding. It can be acute (short-term) or chronic (long-term). Acute immune thrombocytopenic purpura is reported as the most common form and typically affects children whereas chronic form of the disease mostly affects adults.Common immune thrombocytopenic purpura therapeutics include corticosteroids such as prednisone and dexamethasone that work by suppressing immune activity and increasing platelet counts. Intravenous immunoglobulin (IVIg) is another first-line treatment that temporarily increases platelet counts by modulating the immune response. Advancements in ITP therapeutics, coupled with evidence-based immune thrombocytopenic purpura treatment guidelines, are anticipated to improve patient outcomes and support pipeline expansion.
Immune Thrombocytopenic Purpura Epidemiology
Recent epidemiological studies reveal an average estimate of immune thrombocytopenic purpura incidence to be 50 cases per 1,000,000 in children and 66 cases per 1,000,000 in adults each year in the United States. Further, new cases of chronic refractory immune thrombocytopenic purpura are estimated to be 10 cases per 1,000,000 annually in the region.As per the studies conducted in England and Denmark, childhood immune thrombocytopenic purpura occurs in about 10 to 40 cases per 1,000,000 each year.
Immune Thrombocytopenic Purpura - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of immune thrombocytopenic purpura drug candidates based on several segmentations including:By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The pipeline assessment report covers 50+ drug analyses based on drug classes:
- Monoclonal Antibody
- Peptides
- Polymer
- Small Molecule
- Gene Therapy
By Route of Administration
The immune thrombocytopenic purpura report assessment covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
Immune Thrombocytopenic Purpura - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials, with a substantial number of immune thrombocytopenic purpura emerging drugs undergoing clinical development.Immune Thrombocytopenic Purpura - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under immune thrombocytopenic purpura pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapy. The immune thrombocytopenic purpura report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for immune thrombocytopenic purpura.Immune Thrombocytopenic Purpura Clinical Trials Therapeutic Assessment - Competitive Dynamics
The report for the immune thrombocytopenic purpura drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed immune thrombocytopenic purpura therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in immune thrombocytopenic purpura clinical trials:- Principia Biopharma, a Sanofi Company
- Takeda
- Novartis Pharmaceuticals
- argenx
- Eli Lilly and Company
- Renata PLC
Immune Thrombocytopenic Purpura - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for immune thrombocytopenic purpura. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of immune thrombocytopenic purpura drug candidates.Efgartigimod IV
Sponsored by argenx, the objective of this multicenter, randomized, double-blinded clinical trial is to investigate the efficacy and safety of immune thrombocytopenic purpura drug candidate Efgartigimod IV for the treatment of primary immune thrombocytopenia in adult patients. The study is under Phase III clinical development and has an estimated 63 participants.Rilzabrutinib
Principia Biopharma, a Sanofi Company, is conducting a Phase II clinical trial aimed at examining the efficacy, pharmacokinetics, and safety of PRN1008, an oral BTK inhibitor, for relapsed immune thrombocytopenia. The interventional study has enrolled about 81 subjects and is expected to be completed by December 2025.Reasons To Buy This Report
The Immune Thrombocytopenic Purpura Drug Report provides a strategic overview of the latest and future landscape of treatments for immune thrombocytopenic purpura. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within immune thrombocytopenic purpura pipeline insights.Key Questions Answered in the Immune Thrombocytopenic Purpura - Pipeline Insight Report
- Which companies/institutions are leading the immune thrombocytopenic purpura drug development?
- What is the efficacy and safety profile of immune thrombocytopenic purpura pipeline drugs?
- Which company is leading the immune thrombocytopenic purpura pipeline development activities?
- What is the current immune thrombocytopenic purpura commercial assessment?
- What are the opportunities and challenges present in the immune thrombocytopenic purpura drug pipeline landscape?
- What is the efficacy and safety profile of immune thrombocytopenic purpura pipeline drugs?
- Which company is conducting major trials for immune thrombocytopenic purpura drugs?
- Which companies/institutions are involved in immune thrombocytopenic purpura collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in immune thrombocytopenic purpura?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Immune Thrombocytopenic Purpura
4 Patient Profile: Immune Thrombocytopenic Purpura
5 Immune Thrombocytopenic Purpura: Epidemiology Snapshot
6 Immune Thrombocytopenic Purpura: Market Dynamics
7 Immune Thrombocytopenic Purpura: Key Facts Covered
8 Immune Thrombocytopenic Purpura, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Immune Thrombocytopenic Purpura Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Immune Thrombocytopenic Purpura Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Immune Thrombocytopenic Purpura Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Immune Thrombocytopenic Purpura Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Immune Thrombocytopenic Purpura, Key Drug Pipeline Companies
